Stock price data from financial markets

Beam Therapeutics' BEAM-101 Shows Superior Results at ASH 2024, Stock Rises

Dec 9, 2024, 12:57 PM

Beam Therapeutics Inc. has reported promising clinical data for its sickle cell gene therapy, BEAM-101, at the American Society of Hematology (ASH) 2024 conference. The therapy has shown an average of 64-65% fetal hemoglobin (HbF) levels in patients, significantly higher than its competitors Reni-cel and Casgevy. BEAM-101's efficient manufacturing process allows for fewer mobilization cycles, with an average of 1.4 cycles, compared to Reni-cel's 4.6 and Casgevy's 4.7. This efficiency could potentially expand the eligible patient population for gene editing therapies. Additionally, Beam's approach includes a novel conditioning regimen using an anti-CD117 antibody, aiming to reduce toxicity and increase the feasibility of the treatment. The company's stock saw a 6.5% increase following the announcement, reflecting positive market sentiment towards the potential of BEAM-101.